Citigroup Inc. restated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note released on Wednesday morning. Citigroup Inc. currently has a GBX 6,000 ($78.32) price target on the biopharmaceutical company’s stock.
A number of other research firms have also commented on AZN. Deutsche Bank AG reissued a buy rating and issued a GBX 5,800 ($75.71) price target on shares of AstraZeneca plc in a research report on Wednesday, October 5th. Bryan, Garnier & Co dropped their price target on shares of AstraZeneca plc from GBX 5,400 ($70.49) to GBX 5,220 ($68.14) and set a buy rating on the stock in a research report on Tuesday, October 4th. Liberum Capital reissued a hold rating and issued a GBX 5,200 ($67.88) price target on shares of AstraZeneca plc in a research report on Tuesday, October 4th. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price target on shares of AstraZeneca plc and gave the company a sell rating in a research report on Tuesday, October 4th. Finally, JPMorgan Chase & Co. reissued a neutral rating and issued a GBX 4,900 ($63.96) price target on shares of AstraZeneca plc in a research report on Monday, October 3rd. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. AstraZeneca plc currently has a consensus rating of Hold and a consensus target price of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) opened at 5092.5127 on Wednesday. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The company’s market capitalization is GBX 64.42 billion. The stock has a 50 day moving average of GBX 5,005.11 and a 200-day moving average of GBX 4,435.88.
The business also recently declared a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were paid a GBX 68.70 ($0.90) dividend. The ex-dividend date was Thursday, August 11th. This represents a dividend yield of 1.37%.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.